Search
Paclitaxel Treatment Options
A collection of 2028 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1453 - 1464 of 2028
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This clinical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2017
Locations: Williamson Medical Center, Frankling, Tennessee +5 locations
Conditions: Breast Cancer
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
Completed
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy with radiation. The chemoradiation included using paclitaxel and carboplatin with daily thoracic radiation to a total dose of 74 Gy. Response rate was determined following the chemotherapy with gemcitabine and carboplatin and evaluated again after the chemoradiation. Treatm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center & Research Insitute, Tampa, Florida
Conditions: Lung Cancer
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2017
Locations: Poudre Valley Hospital, Fort Collins, Colorado +140 locations
Conditions: Carcinoma of Unknown Primary Origin
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Completed
The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2017
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Urologic Neoplasm
Study of Gemcitabine and Abraxane for Pancreas Cancer
Terminated
A Phase II trial of gemcitabine plus nab-paclitaxel in the second line setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2017
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Pancreatic Cancer
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
Terminated
The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
02/10/2017
Locations: Southern Cancer Center, Mobile, Alabama +60 locations
Conditions: Ovarian Cancer
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Completed
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/09/2017
Locations: Research Site, Los Angeles, California +9 locations
Conditions: Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Terminated
This pilot clinical trial studies stereotactic body radiation therapy followed by combination chemotherapy in treating patients with non-small cell lung cancer. Stereotactic body radiation therapy is a specialized radiation therapy that delivers one to five high doses of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue than conventional radiation. Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2017
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer
Unknown
This is a pilot study looking at using stereotactic radiosurgery and full dose chemotherapy to treat stage II and III lung cancer that is not amendable to surgical resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2017
Locations: MD Anderson Cancer Center at Cooper, Camden, New Jersey
Conditions: Non Small Cell Lung Cancer
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Completed
This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/27/2017
Locations: Ironwood Cancer and Research Centers SC, Chandler, Arizona +112 locations
Conditions: Breast Cancer
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
Terminated
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/27/2017
Locations: University Of South Alabama, Mobile, Alabama +92 locations
Conditions: Endometrial Cancer
Sutent + Taxol for Advanced Esophageal Cancer
Completed
Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with other regimens in similar settings. We believe that the combination of paclitaxel and sunitinib malate offer great promise in the treatment of advanced esophageal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/26/2017
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois +14 locations
Conditions: Esophageal Cancer
1453 - 1464 of 2028